Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist
Multiple sclerosis (MS) ranks first for prevalence among diseases affecting the CNS white matter with 2.5 million cases estimated globally. InRussia, the number of cases is about 200 thousand. MS in most cases has a wavy course (periods of exacerbations and remissions), over time the progression of...
Main Author: | N. Yu. Lashch |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2020-03-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5523 |
Similar Items
-
Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application
by: N. Yu. Lashch
Published: (2020-07-01) -
Relevance of first-line drugs for treatment of multiple sclerosis in present-day conditions
by: N. Yu. Lashch
Published: (2020-12-01) -
Monoclonal Antibodies for Multiple Sclerosis Treatment
by: Filipe Palavra
Published: (2015-09-01) -
Treatment escalation vs early high efficacy treatment in multiple sclerosis (cons and pros) (ORP-45)
by: Mohammad Baghbanian
Published: (2023-01-01) -
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)